Loading…
Candel Therapeutics, Inc. is projected to rise to $12.35 by 2027, a +30% move from its current price of $9.49. CADL is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/13/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $9.20 | $9.50 | $9.80 | +0.09% |
| Jul 15 | $9.09 | $9.51 | $9.94 | +0.19% |
| Jul 16 | $9.01 | $9.52 | $10.05 | +0.28% |
| Jul 17 | $8.94 | $9.53 | $10.15 | +0.38% |
| Jul 18 | $8.89 | $9.53 | $10.23 | +0.47% |
| Jul 19 | $8.84 | $9.54 | $10.31 | +0.57% |
| Jul 20 | $8.79 | $9.55 | $10.38 | +0.66% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $8.79 | $9.55 | $10.38 | +0.66% |
| Week 2 | $8.55 | $9.62 | $10.82 | +1.33% |
| Week 3 | $8.38 | $9.68 | $11.18 | +2.00% |
| Week 4 | $8.25 | $9.74 | $11.51 | +2.68% |
| Week 5 | $8.14 | $9.81 | $11.82 | +3.36% |
| Week 6 | $8.05 | $9.87 | $12.11 | +4.04% |
| Week 7 | $7.97 | $9.94 | $12.39 | +4.73% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Candel Therapeutics, Inc. is a healthcare company focused on developing immunotherapies for cancer patients. It is a clinical stage biopharmaceutical company developing CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC).
The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors.
Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts; it was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020.
CADL is currently trading at $9.49 per share. Its market capitalization is $695.33M and it is ranked 2792.
The near-term price outlook for 2026 shows min $4.48, avg $9.49, max $13.75 with a Neutral sentiment. From 2027 onward, the forecast turns bullish, with rising averages and ROIs across years; by 2050 the avg is $168.08 and the max is $328.46, representing strong upside.
A major floor 52.8% below — a decisive break under it would weaken the trend.
The nearest floor, 16.0% below — buyers have tended to step in here.
The nearest ceiling, 9.2% above — a clean break opens room to run.
A major ceiling 22.9% above — clearing it would confirm fresh momentum.
Key CADL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CADL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $9.83 | Sell | $9.76 | Sell |
| MA 10 | $9.93 | Sell | $9.71 | Sell |
| MA 20 | $9.29 | Buy | $9.41 | Buy |
| MA 50 | $8.57 | Buy | $8.53 | Buy |
| MA 100 | $6.94 | Buy | $7.58 | Buy |
| MA 200 | $6.23 | Buy | $6.79 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 54.85 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | 20.20 | Neutral |
| Williams %R (14) | -67.97 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | 4.52 | Buy |
| Bollinger %B (20,2) | 0.57 | Neutral |
| Stochastic %K (14) | 32.03 | Neutral |
| TRIX (15) | 0.78 | Buy |
| Awesome (5,34) | 0.91 | Buy |
| Ultimate (7,14,28) | 37.96 | Neutral |
| Momentum (10) | 0.02 | Buy |
| Aroon Osc (25) | 32.00 | Buy |
| Hull MA (9) | 9.73 | Sell |
| ADX (14) | 24.28 | Buy |
| ATR (14) | 0.24 | Info |
Sentiment is BULLISH; RSI14 is 50. SMA50 is $8.57 and SMA200 is $6.23. The stock has support at $7.97 and resistance at $10.36.
Over the last 30 days, CADL traded within a range of $7.71 to $11.68.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.48 | $9.49 | $13.71 | 0% | Neutral | |
| $9.69 | $12.35 | $16.73 | +30% | Bullish | |
| $11.10 | $14.61 | $20.63 | +54% | Bullish | |
| $12.74 | $17.23 | $25.15 | +82% | Bullish | |
| $16.10 | $22.31 | $33.45 | +135% | Bullish | |
| $19.59 | $27.76 | $42.62 | +192% | Bullish | |
| $22.97 | $33.23 | $52.11 | +250% | Bullish | |
| $26.40 | $38.93 | $62.24 | +310% | Bullish | |
| $25.96 | $39.01 | $63.48 | +311% | Bullish | |
| $27.84 | $42.57 | $70.41 | +349% | Bullish | |
| $47.80 | $79.29 | $140.40 | +736% | Bullish | |
| $87.71 | $167.84 | $327.97 | +16.7x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $4.48 | $9.49 | $11.34 | +0.00% |
| August 2026 | $8.37 | $9.91 | $12.08 | +4.44% |
| September 2026 | $8.66 | $10.34 | $12.77 | +4.35% |
| October 2026 | $8.55 | $10.29 | $12.84 | -0.55% |
| November 2026 | $8.55 | $10.35 | $13.03 | +0.59% |
| December 2026 | $8.87 | $10.80 | $13.71 | +4.35% |
Click any year to see its month-by-month CADL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, CADL is projected to trade between $4.48 and $13.71, averaging $9.49 — a potential gain of 0% from today's $9.49. A consolidation phase looks the most probable path here.
Candel Therapeutics, Inc.'s 2027 outlook centres on $12.35, within a $9.69 to $16.73 range. That is up +30% on the projected 2026 average. That marks a +30% change versus current levels. Momentum favours further upside here.
By 2028, CADL could reach as high as $20.63, with a base case around $14.61 and support toward $11.10 — roughly +54% from $9.49. Buyers look set to stay in control over this stretch.
Expect CADL to range from $12.74 to $25.15 through 2029. The $17.23 average target implies a +82% move from current prices. That is up +18% on the projected 2028 average. Momentum favours further upside here.
The CADL price prediction for 2030 points to an average of $22.31 (low $16.10, high $33.45) — a potential gain of +135% on today's $9.49. Buyers look set to stay in control over this stretch.
In 2031, CADL is projected to trade between $19.59 and $42.62, averaging $27.76 — a potential gain of +192% from today's $9.49. That is up +24% on the projected 2030 average. Momentum favours further upside here.
Candel Therapeutics, Inc.'s 2032 outlook centres on $33.23, within a $22.97 to $52.11 range. That is up +20% on the projected 2031 average. That marks a +250% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, CADL could reach as high as $62.24, with a base case around $38.93 and support toward $26.40 — roughly +310% from $9.49. Momentum favours further upside here.
Expect CADL to range from $25.96 to $63.48 through 2034. The $39.01 average target implies a +311% move from current prices. That is up 0% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The CADL price prediction for 2035 points to an average of $42.57 (low $27.84, high $70.41) — a potential gain of +349% on today's $9.49. Momentum favours further upside here.
In 2040, CADL is projected to trade between $47.80 and $140.40, averaging $79.29 — a potential gain of +736% from today's $9.49. That is up +86% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Candel Therapeutics, Inc.'s 2050 outlook centres on $167.84, within a $87.71 to $327.97 range. That is up +112% on the projected 2040 average. That marks a +16.7x change versus current levels. Momentum favours further upside here.
Investing $1,000 in CADL today (≈ 105.374078 CADL) could be worth
$17,685.89
+$16,685.89 (+1669%) by 2050 · US Dollar
Based on the average projected CADL price of $167.84 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CADLwould be worth at today's price.
$1,000 invested in CADL on Jul 10, 2025 (≈ 162.601623 CADL) would be worth
$1,543.09
+$543.09 (+54.3%) today · 1.54× · US Dollar
Based on a CADL entry price of $6.15 vs. today's $9.49.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $9.83 | $965.41 | -3.5% |
| 1 month ago | $8.35 | $1,136.53 | +13.7% |
| 3 months ago | $4.83 | $1,964.8 | +96.5% |
| 6 months ago | $5.86 | $1,619.45 | +61.9% |
| 1 year ago | $6.15 | $1,543.09 | +54.3% |
| All time (5.0y) ago | $7 | $1,355.71 | +35.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CADL forecast.
Our base-case forecast reaches $19.00 around 2030.
Implied market cap at $19.00: $1.39B
The multi-year forecast shows bullish sentiment from 2027 onward. In 2030 the forecast lists an average price of $22.26 with a min of $16.06 and a max of $33.39, and an ROI of 134.6.
In 2040 the average is $79.45 with a min of $47.89 and a max of $140.68, and an ROI of 737.1. In 2050 the average is $168.08 with a min of $87.83 and a max of $328.46, and an ROI of 1671.1. These are estimates, not guarantees, and outcomes depend on market conditions and other factors.
Tap a question to reveal the answer.
2030: min $16.06, avg $22.26, max $33.39; ROI 134.6; sentiment BULLISH.
Forecasts show bullish sentiment from 2027 onward with rising averages and ROI; 2026 is Neutral. These are estimates, not guarantees.
2035: min $27.87, avg $42.62, max $70.51; ROI 349.1; sentiment BULLISH.
Current price is $9.49 and market cap is $695.33M.
2040: min $47.89, avg $79.45, max $140.68; ROI 737.1; sentiment BULLISH.
Candel Therapeutics, Inc. Community Discussion
0Share your Candel Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.